Targeting the extrinsic apoptosis signaling pathway for cancer therapy

Cancer Immunology, Immunotherapy

Volumn 60, Issue 8, 2011, Pages 1173-1180

  Sayers, Thomas J ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Bortezomib; Death receptors; Extrinsic apoptosis; Proteasome inhibition; TRAIL

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC ALKALOID; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CASPASE 8; CD137 ANTIBODY; CD40 ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CUCURBITACIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEATH RECEPTOR 5 ANTIBODY; FLICE INHIBITORY PROTEIN; MONOCLONAL ANTIBODY; OBATOCLAX; PROTEASOME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; WITHAFERIN A; WITHANOLIDE; WITHANOLIDE E; X LINKED INHIBITOR OF APOPTOSIS;

ADOPTIVE TRANSFER; APOPTOSIS; CANCER THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79960913158     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1008-4     Document Type: Review

References (59)

1. L Coultas A Strasser 2003 The role of the Bcl-2 protein family in cancer Semin Cancer Biol 13 115 123 12654255 10.1016/S1044-579X(02)00129-3 1:CAS:528:DC%2BD3sXitlWnsLw%3D (Pubitemid 36315930)
2. DR Green GP Marante-Mendes 1998 The point of no return: mitochondria, caspases, and the commitment to cell death Results Probl Cell Differ 24 45 61 9949831 1:CAS:528:DyaK1MXls1eitg%3D%3D
3. GS Salvesen CS Duckett 2002 IAP proteins: blocking the road to death's door Nat Rev Mol Cell Biol 3 401 410 12042762 10.1038/nrm830 1:CAS:528:DC%2BD38XltlartL4%3D (Pubitemid 34685698)
4. F Gonzalvez A Ashkenazi 2010 New insights into apoptosis signaling by Apo2L/TRAIL Oncogene 29 4752 4765 20531300 10.1038/onc.2010.221 1:CAS:528:DC%2BC3cXntVSqsrw%3D
5. CNAM Oldenhuis JH Stegehuis AME Walenkamp S de Jong EGE de Vries 2008 Targeting TRAIL death receptors Curr Opin Pharmacol 8 433 439 18625341 10.1016/j.coph.2008.06.011 1:CAS:528:DC%2BD1cXhtFCktL%2FO
6. A Ashkenazi RS Herbst 2008 To kill a tumor cell: the potential of proapoptotic receptor agonists J Clin Invest 118 1979 1990 18523647 10.1172/JCI34359 1:CAS:528:DC%2BD1cXntVCmsbc%3D (Pubitemid 351872316)
7. SR Wiley K Schooley PJ Smolak WS Din C-P Huang JK Nicholl GR Sutherland CA Smith RG Goodwin 1995 Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673 682 8777713 10.1016/1074-7613(95)90057-8 1:CAS:528:DyaK28XhtF2iug%3D%3D (Pubitemid 26091143)
8. RM Pitti SA Marsters S Ruppert CJ Donahue A Moore A Ashkenazi 1996 Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem 271 12687 12690 8663110 10.1074/jbc.271.22. 12687 1:CAS:528:DyaK28XjtlGjtrc%3D (Pubitemid 26175834)
9. ME Peter PH Krammer 2003 The CD95(APO-1/Fas) DISC and beyond Cell Death Differ 10 26 35 12655293 10.1038/sj.cdd.4401186 1:CAS:528:DC%2BD3sXit12mu70%3D (Pubitemid 36511830)
10. M Irmler M Thome M Hahne P Schneider K Hofmann V Steiner JL Bodmer M Schroter K Burns C Mattmann D Rimoldi LE French J Tschopp 1997 Inhibition of death receptor signals by cellular FLIP Nature 388 190 195 9217161 10.1038/40657 1:CAS:528:DyaK2sXksFWlur0%3D (Pubitemid 27297457)
11. KW Wagner EA Punnoose T Januario DA Lawrence RM Pitti K Lancaster D Lee M von Goetz SF Yee K Totpal L Huw V Katta G Cavet SG Hymowitz L Amler A Ashkenazi 2007 Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nat Med 13 1070 1077 17767167 10.1038/nm1627 1:CAS:528:DC%2BD2sXhtVSgtrvO (Pubitemid 47517508)
12. Z Jin Y Li R Pitti D Lawrence VC Pham JR Lill A Ashkenazi 2009 Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling Cell 137 721 735 19427028 10.1016/j.cell.2009.03.015 1:CAS:528:DC%2BD1MXosVClt7o%3D
13. C Scaffidi I Schmitz J Zha SJ Korsmeyer PH Krammer ME Peter 1999 Differential modulation of apoptosis sensitivity in CD95 type I and type II cells J Biol Chem 274 22532 22538 10428830 10.1074/jbc.274.32.22532 1:CAS:528:DyaK1MXlt1CnsLg%3D (Pubitemid 29379295)
14. N Ozoren WS el Deiry 2002 Defining characteristics of Types I and II apoptotic cells in response to TRAIL Neoplasia 4 551 557 12407450 10.1038/sj.neo.7900270 (Pubitemid 35417080)
15. H Li H Zhu CJ Xu J Yuan 1998 Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis Cell 94 491 501 9727492 10.1016/S0092-8674(00)81590-1 1:CAS:528:DyaK1cXlslOrsbY%3D (Pubitemid 28391865)
16. X Luo I Budihardjo H Zou C Slaughter X Wang 1998 Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors Cell 94 481 490 9727491 10.1016/S0092-8674(00)81589-5 1:CAS:528:DyaK1cXlslOrsbw%3D (Pubitemid 28391864)
17. D Mahalingam E Szegezdi M Keane S de Jong A Samali 2009 TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35 280 288 19117685 10.1016/j.ctrv.2008.11.006 1:CAS:528:DC%2BD1MXksVantrY%3D
18. TJ Sayers WJ Murphy 2006 Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy Cancer Immunol Immunother 55 76 84 15864587 10.1007/s00262-005-0676-3 1:CAS:528: DC%2BD2MXhtlSntrjM (Pubitemid 41783297)
19. TM Ganten R Koschny TL Haas J Sykora M Li-Weber K Herzer H Walczak 2005 Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL Hepatology 42 588 597 16037944 10.1002/hep.20807 1:CAS:528:DC%2BD2MXhtVemt7zK (Pubitemid 41233651)
20. R Koschny TM Ganten J Sykora TL Haas MR Sprick A Kolb W Stremmel H Walczak 2007 TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window Hepatology 45 649 658 17326159 10.1002/hep.21555 1:CAS:528:DC%2BD2sXjs1Gkurg%3D (Pubitemid 46450616)
21. A Shanker AD Brooks CA Tristan JW Wine PJ Elliott H Yagita K Takeda MJ Smyth WJ Murphy TJ Sayers 2008 Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody J Natl Cancer Inst 100 649 662 18445820 10.1093/jnci/djn113 1:CAS:528:DC%2BD1cXlslymtbk%3D
22. J Adams VJ Palombella EA Sausville J Johnson A Destree DD Lazarus J Maas CS Pien S Prakash PJ Elliott 1999 Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 2615 2622 10363983 1:CAS:528:DyaK1MXjs1ymsbY%3D (Pubitemid 29269108)
23. X Liu P Yue S Chen L Hu S Lonial FR Khuri SY Sun 2007 The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells Cancer Res 67 4981 4988 17510429 10.1158/0008-5472.CAN-06-4274 1:CAS:528:DC%2BD2sXltl2gtr8%3D (Pubitemid 46910207)
24. K Kandasamy AS Kraft 2008 Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region Mol Cancer Ther 7 1091 1100 18483298 10.1158/1535-7163.MCT-07-2368 1:CAS:528:DC%2BD1cXlvFanu7w%3D
25. R Koschny H Holland J Sykora TL Haas MR Sprick TM Ganten W Krupp M Bauer P Ahnert J Meixensberger H Walczak 2007 Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Clin Cancer Res 13 3403 3412 17545549 10.1158/1078-0432.CCR-07-0251 1:CAS:528:DC%2BD2sXmtVaisrc%3D (Pubitemid 46944929)
26. TA Luster JA Carrell K McCormick D Sun R Humphreys 2009 Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib Mol Cancer Ther 8 292 302 19174554 10.1158/1535-7163.MCT-08-0918 1:CAS:528:DC%2BD1MXhvFams7c%3D
27. AD Brooks KM Jacobsen W Li A Shanker TJ Sayers 2010 Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex Mol Cancer Res 8 729 738 20442297 10.1158/1541-7786.MCR-10-0022 1:CAS:528:DC%2BC3cXmtFams7s%3D
28. TJ Sayers AD Brooks CY Koh W Ma N Seki A Raziuddin BR Blazar X Zhang PJ Elliott WJ Murphy 2003 The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP Blood 102 303 310 12637321 10.1182/blood-2002-09-2975 1:CAS:528:DC%2BD3sXltFelsr8%3D (Pubitemid 36759669)
29. AF Kabore J Sun X Hu K McCrea JB Johnston SB Gibson 2006 The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells Apoptosis 11 1175 1193 16699949 10.1007/s10495-006-8048-9 1:CAS:528:DC%2BD28Xmslansbo%3D (Pubitemid 44035966)
30. M Nikrad T Johnson H Puthalalath L Coultas J Adams AS Kraft 2005 The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim Mol Cancer Ther 4 443 449 15767553 1:CAS:528:DC%2BD2MXit1Knsrs%3D (Pubitemid 40443929)
31. N Seki U Toh TJ Sayers T Fujii M Miyagi Y Akagi J Kusukawa M Kage K Shirouzu H Yamana 2010 Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways Mol Cancer Ther 9 1842 1851 20515944 10.1158/1535-7163.MCT-09-0918 1:CAS:528:DC%2BC3cXntFGgurk%3D
32. NL Booth TJ Sayers AD Brooks CL Thomas K Jacobsen EI Goncharova JB McMahon CJ Henrich 2009 A cell-based high-throughput screen to identify synergistic TRAIL sensitizers Cancer Immunol Immunother 58 1229 1244 19089423 10.1007/s00262-008-0637-8
33. T-J Lee HJ Um DS Min J-W Park KS Choi TK Kwon 2009 Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP Free Radic Biol Med 46 1639 1649 19345731 10.1016/j.freeradbiomed.2009.03.022 1:CAS:528:DC%2BD1MXlslWltL0%3D
34. AH Lee NN Iwakoshi KC Anderson LH Glimcher 2003 Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Proc Natl Acad Sci USA 100 9946 9951 12902539 10.1073/pnas.1334037100 1:CAS:528:DC%2BD3sXmvVeju7o%3D (Pubitemid 37087048)
35. ST Nawrocki JS Carew K Dunner Jr LH Boise PJ Chiao P Huang JL Abbruzzese DJ McConkey 2005 Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells Cancer Res 65 11510 11519 16357160 10.1158/0008-5472.CAN-05-2394 1:CAS:528: DC%2BD2MXhtlWiu73O (Pubitemid 41821709)
36. S Huang FA Sinicrope 2008 BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells Cancer Res 68 2944 2951 18413764 10.1158/0008-5472.CAN-07-2508 1:CAS:528:DC%2BD1cXks1Ghsr4%3D (Pubitemid 351556295)
37. M Nguyen RC Marcellus A Roulston M Watson L Serfass M Murthy Sr D Goulet J Viallet L Belec X Billot S Acoca E Purisima A Wiegmans L Cluse RW Johnstone P Beauparlant GC Shore 2007 Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc Natl Acad Sci USA 104 19512 19517 18040043 10.1073/pnas.0709443104 1:CAS:528:DC%2BD1cXisVOgsA%3D%3D
38. Z Xu H Friess M Solioz S Aebi M Korc J Kleeff MW Buchler 2001 Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine Int J Cancer 94 268 274 11668508 10.1002/ijc.1447 1:CAS:528:DC%2BD3MXntVGksrY%3D (Pubitemid 32911423)
39. EC LaCasse GG Cherton-Horvat KE Hewitt LJ Jerome SJ Morris ER Kandimalla D Yu H Wang W Wang R Zhang S Agrawal JW Gillard JP Durkin 2006 Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis Clin Cancer Res 12 5231 5241 16951243 10.1158/1078-0432.CCR-06-0608 1:CAS:528:DC%2BD28XovF2gtrY%3D (Pubitemid 44453353)
40. S Fulda W Wick M Weller KM Debatin 2002 Smac agonists sensitize for Apo2L/T-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo Nat Med 8 808 815 12118245 1:CAS:528:DC%2BD38Xls12msbw%3D
41. M Vogler H Walczak D Stadel TL Haas F Genze M Jovanovic U Bhanot C Hasel P Moller JE Gschwend T Simmet KM Debatin S Fulda 2009 Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma Cancer Res 69 2425 2434 19258513 10.1158/0008-5472.CAN-08-2436 1:CAS:528:DC%2BD1MXjtFyqtbY%3D
42. Z Wang M Cuddy T Samuel K Welsh A Schimmer F Hanaii R Houghten C Pinilla JC Reed 2004 Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors J Biol Chem 279 48168 48176 15337764 10.1074/jbc.M405022200 1:CAS:528:DC%2BD2cXptl2ntrc%3D (Pubitemid 39540972)
43. PJ Jost S Grabow D Gray MD McKenzie U Nachbur DC Huang P Bouillet HE Thomas C Borner J Silke A Strasser T Kaufmann 2009 XIAP discriminates between type I and type II FAS-induced apoptosis Nature 460 1035 1039 19626005 10.1038/nature08229 1:CAS:528:DC%2BD1MXovFSrurg%3D
44. TS Griffith RD Anderson BL Davidson RD Williams TL Ratliff 2000 Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis J Immunol 165 2886 2894 10946322 1:CAS:528:DC%2BD3cXmtFOqsr0%3D (Pubitemid 30660741)
45. PA Holoch TS Griffith 2009 TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies Eur J Pharmacol 625 63 72 19836385 10.1016/j.ejphar.2009.06.066 1:CAS:528:DC%2BD1MXhsVGmtb%2FO
46. RL Vanoosten TS Griffith 2007 Activation of tumor-specific CD8+T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy Cancer Res 67 11980 11990 18089829 10.1158/0008-5472.CAN-07-1526 1:CAS:528: DC%2BD2sXhsVCjs7bP
47. T Uno K Takeda Y Kojima H Yoshizawa H Akiba RS Mittler F Gejyo K Okumura H Yagita MJ Smyth 2006 Eradication of established tumors in mice by a combination antibody-based therapy Nat Med 12 693 698 16680149 10.1038/nm1405 1:CAS:528:DC%2BD28XltlOjsb4%3D (Pubitemid 43865240)
48. A Shanker AD Brooks KM Jacobsen JW Wine RH Wiltrout H Yagita TJ Sayers 2009 Antigen presented by tumors in vivo determines the nature of CD8+T-cell cytotoxicity Cancer Res 69 6615 6623 19654302 10.1158/0008-5472.CAN-09-0685 1:CAS:528:DC%2BD1MXpvFejtLs%3D
49. L Chen SM Park AV Tumanov A Hau K Sawada C Feig JR Turner YX Fu IL Romero E Lengyel ME Peter 2010 CD95 promotes tumour growth Nature 465 492 496 20505730 10.1038/nature09075 1:CAS:528:DC%2BC3cXmsF2it7w%3D
50. L Ruggeri M Capanni E Urbani K Perruccio WD Shlomchik A Tosti S Posati D Rogaia F Frassoni F Aversa MF Martelli A Velardi 2002 Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2097 2100 11896281 10.1126/science.1068440 1:CAS:528: DC%2BD38Xit1Ohurs%3D (Pubitemid 34229476)
51. WH Hallett E Ames M Motarjemi I Barao A Shanker DL Tamang TJ Sayers D Hudig WJ Murphy 2008 Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition J Immunol 180 163 170 18097016 1:CAS:528: DC%2BD2sXhsVGjtb3K
52. A Lundqvist H Yokoyama A Smith M Berg R Childs 2009 Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells Blood 113 6120 6127 19202127 10.1182/blood-2008-11-190421 1:CAS:528:DC%2BD1MXnslSmu78%3D
53. A Lundqvist SI Abrams DS Schrump G Alvarez D Suffredini M Berg R Childs 2006 Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity Cancer Res 66 7317 7325 16849582 10.1158/0008-5472.CAN-06-0680 1:CAS:528:DC%2BD28XmvFGkurw%3D (Pubitemid 44197714)
54. I Sudbery AJ Enright AG Fraser I Dunham 2010 Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis BMC Genomics 11 175 20230625 10.1186/1471-2164-11-175
55. P Aza-Blanc CL Cooper K Wagner S Batalov QL Deveraux MP Cooke 2003 Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening Mol Cell 12 627 637 14527409 10.1016/S1097-2765(03)00348-4 1:CAS:528:DC%2BD3sXnvFGrtrg%3D (Pubitemid 37222485)
56. D Ovcharenko K Kelnar C Johnson N Leng D Brown 2007 Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway Cancer Res 67 10782 10788 18006822 10.1158/0008-5472.CAN-07-1484 1:CAS:528:DC%2BD2sXhtlSls7bK (Pubitemid 350145906)
57. TM Yang D Barbone DA Fennell VC Broaddus 2009 Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids Am J Respir Cell Mol Biol 41 14 23 19097992 10.1165/rcmb.2008-0320OC 1:CAS:528:DC%2BD1MXnvF2mur0%3D
58. N Finnberg AJ Klein-Szanto WS El-Deiry 2008 TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis J Clin Invest 118 111 123 18079962 10.1172/JCI29900 1:CAS:528:DC%2BD1cXksFOmuw%3D%3D
59. A Grosse-Wilde O Voloshanenko SL Bailey GM Longton U Schaefer AI Csernok G Schutz EF Greiner CJ Kemp H Walczak 2008 TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development J Clin Invest 118 100 110 18079967 10.1172/JCI33061 1:CAS:528:DC%2BD1cXksFOmug%3D%3D